JAMA Network
About The Study: Muvalaplin was not associated with tolerability concerns and lowered lipoprotein(a) (Lp[a]) levels up to 65% following daily administration for 14 days in this first-in-human phase 1 study involving healthy participants. Lipoprotein(a) is associated with atherosclerotic disease and aortic stenosis. Longer and larger trials will be required to further evaluate safety, tolerability, and effect of muvalaplin on Lp(a) levels and cardiovascular outcomes.
Authors: Stephen J. Nicholls, M.B.B.S., Ph.D., of Monash University in Clayton, Victoria, Australia, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2023.16503)
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
